Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the trading session's close. They were highly encouraged by the specialized ...

TD Cowen has upgraded CRISPR Therapeutics (NASDAQ:CRSP) to hold from sell, stating it now sees less downside to the stock. "We believe Casgevy expectations have bottomed out in the near term and ...

CAR T-cell therapy for cancer leads to similar safety and cancer outcomes in patients with and without preexisting autoimmune ...

Interviews revealed what patients and their caregivers focus on and needed support throughout the CAR-T therapy trajectory.

Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...

The productivity gap in research widens as male researchers utilize AI more effectively. Targeted interventions are needed to ...

Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the momentum, experts worry.

Building a much better scientific enterprise means embracing the idea of collaboration across all aspects of neurodiversity,” ...